The term vulvar intraepithelial neoplasia (VIN) introduced in 1986 incorporates 3 grades of usual VIN (u-VIN I-III) and the differentiated VIN (d-VIN). Although u-VIN is etiologically associated with the human papillomavirus (HPV) infection, d-VIN represents an alternative HPV negative pathway of vulvar carcinogenesis. In 2004, the u-VIN I category was abandoned and u-VIN II and III were merged. Further, an alternative Bethesda-like terminology scheme presenting the term vulvar intraepithelial lesion was proposed recently. To analyze the impact of HPV profiles of vulvar precancerous lesions for their classification and to assess the presumable efficacy of the prophylactic HPV vaccination, 269 vulvar excisions representing lichen sclerosus, lichen simplex chronicus, condylomata acuminata, d-VIN, all grades of u-VIN and squamous cell carcinomas were subjected to the HPV typing by use of GP5+/6+ polymerase chain reaction and reverse line blot hybridization. The results showed different HPV profiles, and also differing frequency of multiple-type HPV infection and the age structure in patients with u-VIN II and III. The biologic heterogeneity within the u-VIN II category was also demonstrated. u-VIN I was distinguished as a rare disorder associated with high-risk HPV infection. We conclude that the original VIN terminology proposed in 1986 seems to be appropriate for the classification of vulvar squamous dysplastic lesions. The spectrum of HPV types found in vulvar squamous cell carcinomas indicates that the efficacy of HPV vaccination in preventing vulvar cancer might be diminished in the studied population, because the recently developed prophylactic vaccines are targeted against a limited number of HPV types.
S quamous precancerous lesions and invasive squamous cell carcinomas (SCCs) of the lower female genital tract are etiologically linked to human papillomavirus (HPV) infection and appertain to the complex of the multicentric lower genital tract squamous neoplasia. 24 Unlike in uterine cervix, the majority of vulvar SCCs are HPV DNA negative 15, 21, 22, 26 with TP53 gene mutations emerging in the environment of vulvar dermatoses such as lichen sclerosus (LS) and lichen simplex chronicus (LSC) as the probable main etiologic factor. 14 On the basis of histologic features, vulvar intraepithelial neoplasia (VIN) has been subdivided into the usual (u-VIN) and differentiated (d-VIN) types. 5 u-VIN is associated with HPV and occurs preferentially in young women at reproductive age. It has been further assorted into warty, basaloid, and mixed subtypes and subclassified into 3 grades (u-VIN I, II, and III). d-VIN affects mainly postmenopausal women and behaves as a carcinoma in situ with a considerable risk of progression into invasive, mostly well differentiated and keratinizing HPV negative SCC. 1 Primarily because of both the low interobserver and intraobserver reproducibility of the u-VIN I category 11 and the doubts about its precancerous potential, the classification proposed by the International Society for the Study of Vulvovaginal Disease (ISSVD) in 1986, 29 and subsequently adopted by World Health Organization, 30 was modified in 2004. 16 Further, an alternative Bethesda-like terminology scheme introducing the term vulvar intraepithelial lesion (VIL) was proposed in 2005 7 (summarized in Table 1 ). To contribute to the current discussion concerning the validity of the newly introduced classifications of vulvar squamous precancerous lesions, we correlated histopathologic and virologic features of vulvar non-neoplastic [LS, LSC, condylomata acuminata (CoA)], precancerous (VIN) and neoplastic (SCC) lesions in a larger series of cases. The presented HPV profiles of particular vulvar lesions might be of value for the estimation of the efficacy of HPV immunization programs, because the recently developed prophylactic vaccines are targeted against a limited spectrum of HPV types. 19 
MATERIALS AND METHODS

Histopathologic Analysis and Case Selection
Patients enrolled into this study were surgically treated for vulvar LS, LSC, CoA, VIN, and SCC in the Faculty Hospital Motol, Prague, Czech Republic in the period from 2000 to 2004. All specimens were taken by the laser skinning vulvectomy or cold knife excision, fixed in 10% buffered formalin immediately after removal, embedded in paraffin and processed according to the standard histopathologic procedures with the hematoxylineosin staining.
Particular categories of lesions (LS, LSC, CoA, VIN, and SCC) were defined according to the criteria described in detail in Table 2 and exemplified in Figure 1 . Every single vulvar excision obtained from a particular patient during the course of the study and also all u-VIN lesions of different grades detected in synchronous multifocal lesions were included. The total of 269 different vulvar lesions from 172 patients were finally enrolled into the study. The spectrum and counts of particular lesions are summarized in Table 3 .
Representative paraffin blocks selected for HPV DNA detection were cut according to the following procedure: The first and the fourth sections (both 4-mm thick) were histopathologically processed and stained with hematoxylin-eosin for the evaluation of a sufficient area of the assessed lesion (>10% of the whole tissue surface). The second and the third section (each of 20-mm thick) were transferred into the sterile Eppendorf tube for the molecular analysis. The cross-contamination of specimens by viral DNA during the cutting was prevented by cleaning the knife of the microtome with the ethanolimpregnated swab. For the detection of a potential contamination, an empty paraffin block was used as a negative control in each series.
DNA Extraction
Paraffin was removed with xylene and DNA was extracted by incubation with proteinase K (Sigma, St Louis, MO) at final concentration 200 mg/mL in lysis buffer (50 mM Tris-HCl, pH 8; 5 mM EDTA, pH 8; 1% Tween 20) for 2 hours at 551C. Proteinase K was inactivated at 951C for 10 minutes and all samples were consequently phenol/chloroform-extracted and stored at À 201C. For every 9 samples, 1 negative control was included in the process of DNA preparation (lysis buffer with proteinase K and no paraffin).
Polymerase Chain Reaction of the Control Gene
A fragment of the human b-globin gene was amplified with primers PC 03 (5 0 ACACAACTGTGT 
HPV Detection and Typing by GP5+/GP6+BIO Reverse Line Blot Hybridization
The presence and typing of the HPV DNA in samples were determined using the reverse line blot hybridization (RLB). 25 This method enables the detection and typing of 37 different HPV types in a single assay. The HPV detection was performed in a PCR thermocycler PTC 200 (MJ Research, Inc, Waltham, MA) by the PCR with primer GP5+ and 5 0 -end biotin labeled GP6+ primer, which amplified the 150 bp long fragment of L1 gene. The PCR was performed for 40 cycles and the biotinylated PCR product was hybridized with the oligonucleotide probes labeled with the 5 0 -terminal amino group. These probes were covalently linked to an activated negatively charged Biodyne C membrane. After washing, the membrane was incubated for 60 minutes at 421C with peroxidase-labeled streptavidin conjugate. For the chemiluminescent detection of hybridizing DNA, the membrane was incubated in ECL detection liquid (Amersham Biosciences, Uppsala, Sweden) and exposed to LumiFilm (Roche, Indianapolis, IN) for 5 minutes.
HPV Typing by a Nucleotide DNA Sequencing
Samples that did not hybridize on the RLB but revealed a clear band on the agarose gel were subjected to 
Epidemiologic Classification of Detected HPV Types
Detected HPV types were stratified into low-risk (LR), high-risk (HR), probably high-risk (pHR), and undetermined-risk (UR) groups according to the recent classification proposed by Munoz et al 9 (Table 4 ).
Statistical Analysis
Statistical calculations were performed using InStat 3.06 statistical software (GraphPad Software, San Diego, CA). The median age of particular groups of patients were compared by unpaired t test with Welch correction. Two-tail P value <0.05 was considered significant.
RESULTS
Data describing the numerical distribution and HPV profiles of the studied lesions are shown in Table  3 . u-VIN represented 87.2% and d-VIN 12.8% of all VIN lesions. The coincidence of both these disorders in a single patient was not detected in our series. In all, 24.2% of u-VIN and 83.3% of d-VIN were associated with a preceding, simultaneous or subsequent vulvar SCC.
HPV Profiles of Vulvar Lesions
Fifteen HPV types from the 37 investigated ones were identified in our specimens by the virologic analysis and their frequency in HPV positive lesions is given in Table 5 and Figure 2 . High prevalence of HPV DNA was found in specimens of u-VIN (98.8%) and CoA (94.7%) being significantly lower in SCC (42.0%). LR-HPV types were identified in 96.3% of HPV positive CoA, whereas 97.6% of HPV positive u-VIN and 93.1% of HPV positive SCC harbored HR-HPV types. The spectrum of detected HPV types was broader in CoA and u-VIN II than in u-VIN I, u-VIN III, and SCC. The most frequently detected HPV types in particular HPV groups were HPV 16, 33, and 45 that represented 93.4% of the HR-HPV group and HPV 6 and 11 comprising 83.8% of the LR-HPV group. HPV 16, 33, and 45 were the only HR-HPV types found in vulvar SCCs. Both groups of LSC and d-VIN contained only one HPV 16 positive case. All lesions classified as LS were HPV DNA negative.
The majority of HPV positive samples (n = 149; 89.8%) contained only one HPV type, but various combinations were detected in the remaining cases with a maximum of 4 different HPV types in a single lesion (2 cases of CoA) ( Fig. 3) . Multiple infections were more 
Age Predilection of Vulvar Lesions
The age distribution of particular patient subgroups is depicted in Figure 5 and the age spectrum of women according to the HPV profile of their vulvar lesions is shown in Figure 6 . The statistical analysis revealed that there was a significant difference in the age distribution between the patients with u-VIN (median age, 53 y) and d-VIN (median age, 79 y) (P<0.0001) and also between those with HPV positive SCC (median age, 64 y) and HPV negative SCC (median age, 77 y) (P = 0.02). The interval between the median age of u-VIN III group (median age, 56 y) and the group of patients with HPV positive SCC was 8 years and such a difference was statistically significant (P = 0.003). On the other hand, the median age of women with d-VIN and patients affected by HPV negative SCC were far closer and differed by 2 years only. The median age of patients with u-VIN II and u-VIN III were significantly different by 14.5 years (P = 0.03), in contrast to the difference between the median age of u-VIN I and u-VIN II groups.
The median age of women with multiple-type infected CoA (median age, 20.5 y) and u-VIN II (median age, 32 y) was lower than the median age of patients with single-type HPV containing CoA (median age, 29 y) and u-VIN II (median age, 51 y). In case of CoA group only, this difference was statistically significant (P = 0.01).
DISCUSSION
HPV Profiles of Vulvar Lesions
Results of our study confirmed that CoA, u-VIN, and a proportion of SCCs contain DNA sequences of HPV. While LR-HPV types dominated in the CoA group, SCC and all 3 grades of u-VIN showed association with HR-HPV types. The group of SCC in our population was strongly linked to HPV 16, 33, and 45, whereas HPV 18, 31, and others that occur worldwide in the SCC of the uterine cervix 2 were not detected in the vulvar SCC in our series. Except from one HPV prevalence study of vulvar lesions performed in a geographically neighboring region, 4 we also found a lower prevalence of HPV 16 and a higher frequency of HPV 33 in u-VIN III and SCC in comparison with other studies, which also used highly sensitive protocols of HPV detection and typing. 15, 18, 24 Accordingly, the geographical variability in the distribution of HPV types was observed previously in the cervical precancerous and neoplastic lesions. 2 The efficacy of prophylactic HPV vaccines in the prevention of vulvar disorders might be, therefore, reduced in our population because neither the recently developed bivalent HPV-16/18 VLP vaccine nor the quadrivalent HPV-6/11/16/18 VLP vaccine is targeted against HPV 33 or 45. 19 Whether the potential cross-neutralizing antibodies possess the protection also against other HPV types remains still unclear. 19 
HPV Negative Vulvar Lesions
In our study, HPV negative lesions were exemplified by vulvar dermatoses (LS and LSC), d-VIN, and by the majority of SCCs, which is in concordance with the proposed model of the 2 independent pathways of the vulvar carcinogenesis. Only 1 case of LSC and d-VIN was HR-HPV (HPV 16) positive and 2 cases of keratinizing SCC in postmenopausal women contained LR-HPV types (HPV 6 and 42). No histologic signs of HPV infection were observed in these 4 lesions. Although occasional association of HPV 6 and 11 with anal, vulvar, and penile SCC was also rarely described, 6 the asymptomatic presence of HPV DNA was noted in various normal human tissues 10, 20 and we consider the HPV positivity in these cases as such coincidental HPV infection.
In our study, the u-VIN and d-VIN differed by their histopathologic pattern, HPV profiles, and age of the patients. The frequency of d-VIN in our series (12.8%) is congruent with previous observations, in which this entity was revealed in 2% 23 to 16% 3 of all VIN cases. Although HPV negative SCC prevailed in the group of vulvar SCC, the frequency of d-VIN was paradoxically lower when compared with the incidence of u-VIN. The discrepancy could be explained by the discrete macroscopic appearance of d-VIN resembling vulvar dermatoses and by the lower frequency of gynecologic examinations in postmenopausal women that result in a possible underdiagnosis of this disorder. Another important factor might be the short preinvasive interval of d-VIN leading to a decreased rate of clinical detection before the stromal invasion appears. 31 Our results support this view through the proximity of the median age of patients affected by d-VIN and HPV negative SCC in contrast to those with corresponding HPV positive lesions. In addition, the d-VIN group in our series revealed a stronger association with the preceding, simultaneous or subsequent SCC occurring in a single patient during the 5-year interval of the study than observed in the u-VIN III group. Importantly, our data showed that the pure histopathologic assessment of the vulvar squamous precancerous lesions correlates well with their HPV status, that it is sufficient to distinguish HPV positive from HPV negative lesions and that such stratification is of a clinical value.
The Multiple-type HPV Infection
In the CoA and u-VIN II groups, we observed a tendency to the multiple-type HPV infection and detected the largest spectrum of HPV types involved. Multipletype infected cases frequently contained HPV types unexpected for the nature of the assessed lesion (LR-HPV in 60% of u-VIN II and HR-HPV in 40% of CoA). The high rate of multiple HPV type infections and the coinfections with HR-HPV types was described in CoA previously 27 and it seems to represent a common feature of these lesions with a possible impact on the efficacy of the therapeutic HPV vaccination. 27 CoA are generally assumed to be polyclonal epithelial proliferations lacking neoplastic properties, which may harbor more HPV types. On the other hand, u-VIN III and SCC are believed to be monoclonal disorders 12 defined by a single cell line proliferation with an integrated genome of one transcriptionally active HR-HPV type. 28 It corresponds with the low rate of multiple-type HPV infections detected in u-VIN III (3%) and none in SCC in our series. However, it contrasts with the 41.7% of u-VIN II being infected with multiple HPV types. The obvious difference between u-VIN II and u-VIN III became more apparent when focusing only on HPV types associated with SCC in the given population (HPV 16, 33, and 45). These types were found in 98.5% of u-VIN III (all of HPV positive cases), but only in 83.3% of u-VIN II. It may indicate that approximately 15% of u-VIN II lesions, containing HPV types not detected in u-VIN III and lacking HPV types strongly associated with u-VIN III, will probably not progress to u-VIN III. Moreover, patients affected by u-VIN II and u-VIN III represented 2 distinct groups significantly differing in their median age of presentation by 14.5 years.
The lower median age of patients with multiple-type infected CoA and u-VIN II implicates that these lesions might evolve in a short interval after the infection before the viral clearance process and clonal selection.
Implications for the Classification of Vulvar Squamous Precancerous Lesions
Both the recently proposed classifications of vulvar squamous dysplastic lesions (ISSVD 2004 and Bethesdalike) merged the u-VIN II and u-VIN III into a single category of u-VIN or high-grade vulvar intraepithelial lesion (HG-VIL). The terms u-VIN (according to the ISSVD 2004) and HG-VIL should be analogous to the high-grade squamous intraepithelial lesions of the uterine cervix, which encompass 2 grades of cervical intraepithelial neoplasia (CIN II and CIN III). However, CIN II and cervical high-grade squamous intraepithelial lesions were recently recognized as a heterogeneous groups of lesions with a different biologic potential, a varying tendency to the regression and a differing spectrum of HPV types involved. 8, 17, 32 In our study, we obtained data indicating similar differences in age characteristics and HPV profiles of u-VIN II and u-VIN III, suggesting a biologic heterogeneity of these lesions. The u-VIN II seems to incorporate the spectrum of either genuine high-grade dysplastic lesions (older patients with single HPV type infected lesions) or HPV associated epithelial proliferations with a minimal or no precancerous potential resembling CoA (younger patients with multiple HPV type infected lesions). Merging of u-VIN II with u-VIN III into one category (u-VIN or HG-VIL) is misleading because of the formation of a wide group of lesions with a various biologic nature and brings a potential risk of overtreatment. As the subtypes of u-VIN II are not reliably distinguishable histologically, the entire category should be regarded as a group of lesions of uncertain precancerous potential rather than high-grade dysplastic lesions only.
A disagreement between the modified terminologic systems remains in the concept of low-grade dysplastic vulvar lesions. While the u-VIN I category was abandoned in the ISSVD 2004 classification, Bethesda-like scheme expanded the term of low-grade VIL with the CoA. Our data demonstrated that u-VIN I is a rare category of vulvar lesions representing only 4.9% of u-VIN. All cases of u-VIN I in our series contained HR-HPV types and were detected in patients presenting previous, simultaneous, or subsequent u-VIN III. We found 1 case of u-VIN I in a patient with a previous HPV positive vulvar SCC and no multiple-type HPV infection was identified in this group. In u-VIN I, the high frequency of HR-HPV (42%) was recently demonstrated. 18 Unfortunately, our results are limited by a lower number of the cases studied so far and an extended research will be desirable to address this issue.
On the basis of our data, we suggest that u-VIN I should be retained in the terminology system to prevent forming a diagnostical window, but it should not merge with the CoA into one category because of the different HPV profiles and frequent coincidence of u-VIN I with u-VIN III. Likewise, in the u-VIN II group, it is difficult to decide histologically whether the alteration of u-VIN I appearance represents a true dysplastic lesion or merely a manifestation of HPV infection. To enhance the reproducibility of the u-VIN I category, the u-VIN I as a HPVrelated disorder should not be confused with vulvar dermatoses or inflammatory conditions. Although features of these lesions might include reactive basal atypia and moderate mitotic activity, the signs of the HPV infection including koilocytosis, prominent nuclear enlargement, or multinucleation are absent. Identically, the manifestation of HPV cytopathic effect is not seen in d-VIN, which may be potentially mistaken for u-VIN I owing to the similar distribution of cytologic atypia and mitotic figures in the basal parts of the squamous epithelium.
CONCLUSIONS
We performed a correlation study between the histologic features and the HPV profile of vulvar non-neoplastic, precancerous, and neoplastic squamous lesions using a high sensitive protocol of HPV detection and typing. Our results indicate that both the revised terminologic systems (ISSVD 2004 and Bethesda-like) might be misleading in the diagnosis and management of vulvar dysplastic lesions owing to both the biologic heterogeneity of the u-VIN II category and the discrepancies in HPV profiles and age of patients with u-VIN II and u-VIN III. Therefore, we suggest that the ISSVD 1986 terminology should be retained as the classification scheme of vulvar dysplastic lesions with respect to the fact that u-VIN II category encompasses epithelial alterations of histologically unpredictable precancerous potential. Moreover, u-VIN I should be perceived as a rare condition occurring mostly in patients with other HPV associated lesions of the vulva or other parts of the lower female genital tract.
Differences in the HPV profiles of vulvar and cervical precancerous and neoplastic squamous lesions and the geographical variability in the distribution of HPV types in vulvar disorders were demonstrated. The increased prevalence of HPV 33 and the decreased frequency of HPV 16 and 18 detected in vulvar lesions investigated in this study might influence the efficacy of the prophylactic HPV vaccination in preventing vulvar cancer, because both the recently developed vaccines are targeted primarily against HPV 16 and 18.
